Evogene Schedules Fourth Quarter and Full Year 2025 Financial Results Release
Rhea-AI Summary
Evogene (NASDAQ: EVGN) will release its fourth quarter and full year 2025 financial results on Thursday, March 5, 2026. Management will discuss results in a Zoom conference call the same day at 9:00 AM ET (4:00 PM Israel time).
Investors must register in advance to attend and the full webcast will be posted on the company's website a few days after the call. Registration link: https://www.veidan-conferencing.com/evogene.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, EVGN declined 8.50%, reflecting a notable negative market reaction. Argus tracked a trough of -5.6% from its starting point during tracking. Our momentum scanner triggered 7 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $729K from the company's valuation, bringing the market cap to $8M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
EVGN was down 3.69% while momentum peers were mixed, with 2 up and 2 down, indicating stock-specific trading rather than a clear sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 schedule | Neutral | -1.7% | Announcement of Q3 2025 results date and conference call details. |
| Aug 19 | Q2/H1 2025 results | Positive | -4.2% | Reported higher H1 2025 revenue and lower operating expenses year over year. |
| Jul 29 | Q2 2025 schedule | Neutral | -2.3% | Set Q2 2025 results release date and investor call logistics. |
| May 21 | Q1 2025 results | Negative | -6.7% | Reported Q1 2025 revenue decline versus 2024 despite cost reductions. |
| May 08 | Q1 2025 schedule | Neutral | -0.9% | Announced Q1 2025 results timing and related conference call. |
Around earnings-related announcements, EVGN has typically traded lower, with only one earnings event showing aligned negative reaction to weaker results and several scheduling/earnings updates seeing downside despite neutral or positive fundamentals.
Over the past year, Evogene’s earnings cycle has featured multiple scheduling notices and two detailed results releases. On May 8, 2025 and July 29, 2025, it announced Q1 and Q2 2025 release dates, with modest subsequent declines. Results on May 21, 2025 showed revenue falling to $2.4M from $4.2M, while Q2/H1 data on August 19, 2025 highlighted H1 revenues rising to $3.2M and sizable cost reductions, yet shares still moved lower around those updates.
Historical Comparison
Past earnings-tagged news for EVGN led to an average move of -3.16%, often skewing negative even when fundamentals or updates were neutral to positive, similar to this scheduling announcement.
Earnings-related releases have tracked Evogene’s 2025 transition: Q1 showed revenue pressure and cost cuts, while H1 highlighted revenue growth and restructuring outcomes, interspersed with routine scheduling notices ahead of each results date.
Market Pulse Summary
The stock moved -8.5% in the session following this news. A negative reaction despite this being only a scheduling notice would fit prior earnings-tagged behavior, where the average move was -3.16% and even positive fundamentals sometimes coincided with declines. Past Q1 and H1 2025 releases showed revenue fluctuations and restructuring activity, so traders may have used the date announcement as a moment to reposition ahead of detailed numbers.
AI-generated analysis. Not financial advice.
Zoom conference call scheduled for March 5, 2026, 9:00 AM ET
REHOVOT,
Later that day, Company management will host a conference call to discuss the results at 9:00 AM Eastern Time (4:00 PM Israel time).
To attend the conference, please register in advance:
https://www.veidan-conferencing.com/evogene
The entire conference will be available online on the company's website a few days after.
About Evogene
Evogene Ltd. (Nasdaq/TASE: EVGN) is a pioneering company in computational chemistry, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries.
At the core of its technology is ChemPass AI™, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs.
Built on this powerful technological foundation, and through strategic partnerships alongside internal product development, Evogene is focused on creating breakthrough products driven by the integration of scientific innovation with real-world industry needs. We call this approach "Real-World Innovation".
Learn more at: www.evogene.com.
Contact
ir@evogene.com
Tel: +972-8-9311901
Logo: https://mma.prnewswire.com/media/2814604/Evogene_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/evogene-schedules-fourth-quarter-and-full-year-2025-financial-results-release-302692436.html
SOURCE Evogene
FAQ
When will Evogene (EVGN) release fourth quarter and full year 2025 results?
How can investors attend the Evogene (EVGN) March 5, 2026 conference call?
What time is the Evogene (EVGN) conference call for the March 5, 2026 results?
Will the Evogene (EVGN) earnings webcast be available after the March 5, 2026 call?
What topics will Evogene (EVGN) management cover on the March 5, 2026 call?
Where can I find registration and replay information for Evogene (EVGN) March 5, 2026 event?
